Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Total Non-Current Liabilities (2020 - 2023)

Terns Pharmaceuticals' Total Non-Current Liabilities history spans 4 years, with the latest figure at $12.1 million for Q3 2023.

  • For Q3 2023, Total Non-Current Liabilities rose 48.48% year-over-year to $12.1 million; the TTM value through Sep 2023 reached $12.1 million, up 48.48%, while the annual FY2022 figure was $9.0 million, 29.11% up from the prior year.
  • Total Non-Current Liabilities reached $12.1 million in Q3 2023 per TERN's latest filing, down from $14.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $23.0 million in Q4 2020 to a low of $6.0 million in Q2 2021.
  • Average Total Non-Current Liabilities over 4 years is $10.2 million, with a median of $8.4 million recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: tumbled 69.71% in 2021, then soared 109.73% in 2023.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $23.0 million in 2020, then crashed by 69.71% to $7.0 million in 2021, then increased by 29.11% to $9.0 million in 2022, then surged by 34.82% to $12.1 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Total Non-Current Liabilities are $12.1 million (Q3 2023), $14.5 million (Q2 2023), and $12.5 million (Q1 2023).